Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (R01 NS084959, R01 NS084959, R01 NS084959)
Article History
Received: 15 April 2024
Accepted: 21 May 2024
First Online: 11 June 2024
Declarations
:
: JAK serves on the Scientific Advisory Boards of the Dravet Syndrome Foundation and FamilieSCN2A Foundation. JAK receives research funding from Praxis Precision Medicines and Neurocrine Biosciences. NAH provides paid consulting services to Takeda Pharmaceuticals. All other authors have declared that no competing interests exist.
: Animal care and experimental procedures were approved by the Northwestern University Animal Care and Use Committee in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.